NASDAQ:IBIO iBio (IBIO) Stock Price, News & Analysis $1.40 -0.03 (-1.82%) Closing price 03:59 PM EasternExtended Trading$1.41 +0.01 (+0.43%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About iBio Stock (NASDAQ:IBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get iBio alerts:Sign Up Key Stats Today's Range$1.40▼$1.4650-Day Range$1.35▼$1.7552-Week Range$0.77▼$3.82Volume318,901 shsAverage Volume1.20 million shsMarket Capitalization$69.75 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company Overview iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas. Read More iBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreIBIO MarketRank™: iBio scored higher than 49% of companies evaluated by MarketBeat, and ranked 595th out of 918 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingBuy Consensus RatingiBio has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 3 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialiBio has a consensus price target of $5.00, representing about 253.4% upside from its current price of $1.42.Amount of Analyst CoverageiBio has only been the subject of 4 research reports in the past 90 days.Read more about iBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for iBio are expected to grow in the coming year, from ($0.36) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iBio is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iBio is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiBio has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about iBio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.41% of the float of iBio has been sold short.Short Interest Ratio / Days to CoveriBio has a short interest ratio ("days to cover") of 11.12, which indicates bearish sentiment.Change versus previous monthShort interest in iBio has recently decreased by 1.52%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.33 News SentimentiBio has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for iBio this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for IBIO on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added iBio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iBio insiders have not sold or bought any company stock.Percentage Held by Insiders2.75% of the stock of iBio is held by insiders.Percentage Held by Institutions7.90% of the stock of iBio is held by institutions.Read more about iBio's insider trading history. Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBIO Stock News HeadlinesiBio (NASDAQ:IBIO) Rating Lowered to "Sell" at Wall Street ZenAugust 23, 2026 | americanbankingnews.comiBio Names Dr. Molly Carr as Chief Medical Officer to Advance Clinical-Stage PipelineAugust 4, 2026 | quiverquant.comQTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.August 27 at 1:00 AM | Altimetry (Ad)iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical OfficerAugust 4, 2026 | globenewswire.comiBio Updates Governance Deadlines for 2026 Annual MeetingJuly 17, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)July 3, 2026 | theglobeandmail.comiBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP StudyJuly 1, 2026 | globenewswire.comCould iBio (IBIO) Be an Underrated Obesity Stock?June 11, 2026 | insidermonkey.comSee More Headlines IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed this year? iBio's stock was trading at $1.93 at the beginning of 2026. Since then, IBIO stock has decreased by 26.7% and is now trading at $1.4150. How were iBio's earnings last quarter? iBio, Inc. (NASDAQ:IBIO) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01. When did iBio's stock split? iBio shares reverse split on the morning of Wednesday, November 29th 2023.The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are iBio's major shareholders? iBio's top institutional shareholders include Headlands Technologies LLC (0.10%). Insiders that own company stock include Felipe Duran, Martin Brenner and David Arkowitz. View institutional ownership trends. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Inovio Pharmaceuticals (INO), NIO (NIO), Plug Power (PLUG), Tesla (TSLA), Advanced Micro Devices (AMD) and Ford Motor (F). Company Calendar Last Earnings5/12/2026Today8/27/2026Next Earnings (Estimated)9/04/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 IBIO's financial health is in the Yellow zone, according to TradeSmith. IBIO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IBIO Previous SymbolNYSEMKT:IBIO CIK1420720 Webibioinc.com Phone(302) 355-0650Fax302-356-1173Employees100Year FoundedN/APrice Target and Rating Average Price Target for iBio$5.00 High Price Target$7.00 Low Price Target$2.00 Potential Upside/Downside+253.4%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.38 million Net MarginsN/A Pretax Margin-9,202.00% Return on Equity-53.86% Return on Assets-46.48% Debt Debt-to-Equity RatioN/A Current Ratio11.88 Quick Ratio11.88 Sales & Book Value Annual Sales$400 thousand Price / Sales175.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book1.57Miscellaneous Outstanding Shares49,680,000Free Float48,313,000Market Cap$70.30 million OptionableN/A Beta1.30 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:IBIO) was last updated on 8/27/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
